SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF

Silence Therapeutics plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$19.58+10.90 (+125.58%)

Close on Oct 19, 2026

Market cap: $2.77B
P/E (TTM): –
Dividend yield: –

Silence Therapeutics plc income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	0.56	43	32	22	–	–	–	–
Cost of Revenue	0.22	12	13	13	–	–	–	–
Gross Profit	0.34	31	19	8.19	–	–	–	–
Research & Development	68	68	57	44	–	–	–	–
General & Administrative	22	27	26	26	–	–	–	–
Operating Income	-91	-63	-64	-61	–	–	–	–
Merger & Restructuring Charges	1.32	0	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	–	–	–	–	–
Pretax Income	-89	-44	-53	-50	–	–	–	–
Income Tax Expense	0.01	0.85	0.96	0.69	–	–	–	–
Net Income incl. Noncontrolling Interests	-89	-45	-54	-50	–	–	–	–
Net Income	-89	-45	-54	-50	–	–	–	–
EPS (Basic)(per share)	-0.63	-0.33	-0.49	-0.52	–	–	–	–
EPS (Diluted)(per share)	-0.63	-0.33	-0.49	-0.52	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	142	139	111	97	89	82	75	70
Shares Outstanding (Diluted, Weighted)(shares)	142	139	111	97	89	82	75	70

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 85.9%
Operating margin: -11106.8%
Net margin: -9748.5%
Return on equity, FY2025: -90.3%

Financial strength

Current ratio: 7.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 566.7%

Valuation

P/E ratio: –
Price to sales: 4511.67
Price to book: 72.12
Dividend yield: –